Press Release · Cytonics Corporation
Cytonics Uses Ten Years of Osteoarthritis Natural-History Data to Shape the Next Stage of CYT-108 Clinical Development
Distributed by Times Beats · Originally issued via PR Newswire

FOCAL analysis of the NIH-sponsored Osteoarthritis Initiative identifies two reproducible structural phenotypes of knee osteoarthritis, including a subgroup that loses joint space about 56% faster
Findings are informing patient selection and endpoint strategy for the planned Phase 1b/2a study of CYT-108 ahead of Cytonics' planned FDA Type C meeting request
JUPITER, Fla., Nov. 18, 2026 — Cytonics Corporation, a clinical-stage biotechnology company developing engineered alpha-2-macroglobulin (A2M) biologics, today announced the completion of the core analysis of FOCAL (Foundational Osteoarthritis Clinical & Analytic Layer). FOCAL is the company's data-science program for studying how knee osteoarthritis progresses and for turning that knowledge into clinical-trial design decisions for CYT-108, its investigational engineered A2M biologic.
FOCAL used ten years of follow-up data from the Osteoarthritis Initiative (OAI), a multi-center, longitudinal, observational study of knee osteoarthritis sponsored by the National Institutes of Health. Using data from the 4,796-participant OAI cohort, Cytonics selected an analytical population of 1,862 participants with Kellgren-Lawrence (KL) grade 2–3 knee osteoarthritis and no prior knee replacement, according to prespecified criteria. It modeled their structural decline on X-ray and MRI, along with their progression to total knee replacement.
Key findings
- Two reproducible structural phenotypes. An unsupervised machine-learning analysis (consensus clustering) divided trial-eligible participants into two groups. About four in ten were Severe-Structural and the rest were Early-Structural. The groups were defined in one half of the cohort and reproduced in the other half, with 98.2% label stability.
- Faster progression in the Severe-Structural group. Over ten years, Severe-Structural participants lost joint space about 56% faster per three-year interval than Early-Structural participants (p<0.001, adjusted for baseline joint space, age, sex, BMI and KL grade). They were about three times as likely to undergo total knee replacement within ten years (16.7% vs. 5.5%).
- Confirmation by two imaging methods. The faster decline appeared both in radiographic joint-space width and in quantitative MRI measurement of cartilage thickness. These are independent measurement methods.
- A candidate trial population. Within the Severe-Structural group, applying a minimum joint-space width of 2.0 mm excludes knees too advanced to show further measurable change. The resulting population held up in held-out data, and about one in six OAI participants with usable baseline X-rays met the criteria. Few participants in this population progressed to knee replacement within three years (2.1%), so dropout from that cause would be limited over a typical study period.
- Bone marrow lesions as an added signal. Bone marrow lesions seen on MRI independently predicted faster structural progression. This finding comes from a smaller subset of participants with MRI scoring data and is considered preliminary.
All FOCAL findings describe the natural course of disease in untreated OAI participants. They do not show or imply any effect of CYT-108.
How FOCAL is guiding clinical development
FOCAL was set up to answer one question before more patients are enrolled: what would it take to detect a meaningful treatment effect in knee osteoarthritis?
The answers are already changing Cytonics' clinical development plans in three ways.
Who to enroll. The phenotype and joint-space criteria give Cytonics a candidate way to enrich the planned Phase 1b/2a study for patients whose disease is active and still measurable.
What to measure, and when. The data show how slowly structure changes, even in faster-progressing patients. The analysis indicates that a trial designed to show a structural benefit would likely need about three years of follow-up and roughly 175 to 300 patients. Based on these results, Cytonics' clinical team concluded that structural measures are not appropriate primary endpoints for an early-stage study. The planned Phase 1b/2a study is being designed to evaluate safety and pain along an escalating dose range. Joint-space width and MRI cartilage measures will be assessed as exploratory endpoints. Disease modification remains the long-term development goal for CYT-108, and FOCAL now gives the company a quantitative basis for designing the longer trials that goal will require.
How to reduce noise. Bone marrow lesions predict structural progression, but they are also associated with knee pain. Cytonics is therefore evaluating whether to stratify or restrict enrollment by lesion status to protect the reliability of pain measurements. The FOCAL team is also reviewing the pain data available in the OAI to inform recruitment criteria and approaches to limiting placebo response, which is a recurring challenge in osteoarthritis trials.
"Osteoarthritis trials have a long history of falling short. Often that happens because the disease moves too slowly, or too unevenly, for a study to see a treatment effect. The drug itself may never get a fair test," said Joey Bose, President and Chief Executive Officer of Cytonics. "Before asking more patients to take part in a study of CYT-108, we wanted to understand the disease we are trying to change. Ten years of untreated natural history told us who progresses, how fast, and how long it takes to see structural change. We are modifying our clinical approach to match that evidence. FOCAL is now a working tool for important design decisions ahead of us."
"Our next study needs to answer clear clinical questions: how well CYT-108 is tolerated across the planned doses and whether it shows preliminary signs of benefit for patients," said Tracy Goeken, MD, Chief Medical Officer of Cytonics. "FOCAL helps us evaluate candidate patient-selection criteria and the time needed to assess structural change. We plan to prioritize safety, tolerability and dose selection while exploring effects on pain and physical function. Structural assessments would generate hypotheses for longer-term studies; this early study is not intended to establish disease modification."
Why the approach is distinctive
Early-stage osteoarthritis trials are often designed around assumed rates of progression. FOCAL replaced those assumptions with modeled estimates from one of the largest long-term natural-history datasets in knee osteoarthritis. The analysis also built in validation steps that are uncommon at this stage of development: the phenotypes were derived and then reproduced in independent halves of the cohort, findings were confirmed across two imaging methods, and the patient-selection threshold was tested in held-out data. Over the course of the work, Cytonics also corrected its own earlier estimates. It moved to an adjudicated knee-replacement registry and a more conservative statistical model before finalizing any conclusions.
Cytonics intends to extend FOCAL as new data become available, including data from its ongoing preclinical pharmacokinetic/pharmacodynamic program.
Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the progress of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company's product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company's product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that the Company may incur operating expenses in amounts greater than anticipated.
SOURCE Cytonics Corporation
About FOCAL
FOCAL (Foundational Osteoarthritis Clinical & Analytic Layer) is Cytonics' data-science program for osteoarthritis. It combines longitudinal natural-history data with CYT-108's biological mechanism to inform clinical development decisions. The analysis described here was led by Manjunath Kustagi, AI Engineer – Computational Biology, working with Cytonics' clinical development team. The findings are internal analyses of observational data. They have not been peer-reviewed or reviewed by any regulatory authority.
Data and/or research tools used in the preparation of this release were obtained and analyzed from the controlled access datasets distributed from the Osteoarthritis Initiative (OAI), a data repository housed within the NIMH Data Archive (NDA). OAI is a collaborative informatics system created by the National Institute of Mental Health and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) to provide a worldwide resource to quicken the pace of biomarker identification, scientific investigation and OA drug development. Dataset identifier(s): NIMH Data Archive Collection ID 2343. This release does not claim or imply endorsement by the NIH, NIMH or NIAMS of Cytonics, its research or CYT-108.
About CYT-108
CYT-108 is an investigational recombinant variant of the endogenous alpha-2-macroglobulin (A2M) blood serum protein. The "bait" region of the protein, which serves as a substrate for proteases, was engineered to increase its affinity for specific proteases that are known to play a significant role in the molecular pathogenesis of osteoarthritis. The combination of both highly specific and broad-spectrum protease inhibition activity of CYT-108 differentiates this novel biologic from other attempts to develop small molecule inhibitors that target a single protease, positioning CYT-108 as an ideal disease-modifying candidate for osteoarthritis. The development of CYT-108 is predicated on the success of Cytonics' first-generation therapy, the Autologous Protease Inhibitor Concentrate (APIC) system, which is a 510(k) medical device that selectively enriches autologous A2M for intra-articular injection into joints containing articular cartilage (knee, shoulder, spine, hip, etc.). The clinical and commercial success of APIC uniquely de-risks the development of CYT-108 because it is already understood that high concentrations of A2M can be introduced into arthritic joints without significant side effects, and the treatment has achieved clinical and commercial success since it was first cleared by the FDA as a 510(k) device and sold in 2015.
About Cytonics Corp.
Cytonics, founded in 2006, is a private research and development company focused on developing molecular diagnostics and therapeutics for chronic musculoskeletal diseases such as osteoarthritis. The company's flagship product was a diagnostic test (the Fibronectin-Aggrecan Complex Test, FACT) which helps identify the source of joint pain and assists physicians in determining the most appropriate course of treatment. Cytonics then developed the APIC system which concentrates a therapeutic blood protein, A2M, from patients' own blood and injects the A2M-rich concentrate into damaged joints. APIC has been used to treat over 8,000 patients nationwide, saving thousands of patients from invasive joint replacement surgeries. The company has raised over $25M in private funding and was awarded $1.8M in grants from the NIH to pursue their innovative research. The company is planning a Phase 1b/2a clinical study for their lead drug candidate, CYT-108, a recombinant variant of the endogenous alpha-2-macroglobulin protease inhibitor. If approved, CYT-108 may be the first and only disease-modifying therapy for osteoarthritis.
Learn more: www.cytonics.com